



DEPARTMENT OF HEALTH & HUMAN SERVICES

---

National Institutes of Health  
Bethesda, Maryland 20892

July 1, 2015

J. Donald Easton, M.D.  
Clinical Professor  
UCSF Department of Neurology  
Sandler Neurosciences Center  
675 Nelson Rising Lane  
San Francisco, CA 94158-0663

Dear Dr. Easton:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met in Portland, OR on June 8, 2015 to review all interim data from the trial. The DSMB did not identify any concerns regarding safety or study implementation, and thus recommended the study proceed as planned.

The DSMB will meet in approximately six months to perform the next interim review.

Sincerely,

A handwritten signature in blue ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc.M.  
Clinical Research Project Manager  
Office of Clinical Research  
National Institute of Neurological Disorders and Stroke  
National Institutes of Health  
6001 Executive Boulevard, Suite 2202  
Bethesda, MD 20892-9525